aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman

Company Overview - aTyr Pharma, Inc. experienced a significant decline in share price, dropping over 80% following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint [1][5]. Market Reaction - The market reacted severely to the topline results call on September 15, 2025, where aTyr reported that the trial failed to achieve statistical significance in steroid reduction, with placebo tapering outperforming the company's expectations [5]. Investigation Details - Hagens Berman, a national shareholders rights firm, has initiated an investigation into aTyr for potentially misleading investors regarding the Phase 2 data and the design of the Phase 3 EFZO-FIT™ trial [2][6]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 efzofitimod data and the trial design [3][6]. Company Claims - aTyr previously assured investors that its Phase 2 data was among the best seen by experts and claimed that efzofitimod could dominate the ILD market, which was described as a multi-billion-dollar opportunity [4][6].